Press Releases

Jun 08, 2022
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
Completed Phase I dose escalation; results expected in 3Q22 CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®
Jun 01, 2022
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Jun. 1, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will
Displaying 1 - 10 of 13